盤中異動 | 藥明生物升6%創5個月新高,機構料全年業績持續高增
1月11日,$藥明生物(02269.HK)$持續走高,股價漲超6%,創近5個月來新高。截至發稿,藥明生物漲6.08%,報71.5港元,成交額10.83億港元。
消息面上,針對公司與GSK就多款創新TCE雙抗/多抗達成許可協議事件,有機構點評稱,WuXiBody雙抗平臺價值不斷凸顯,CRDMO商業模式“R”的價值持續兌現。CMO持續放量,跟隨並贏得分子策略有望帶動全年持續高增。
另外,據聯交所數據顯示,近三月,南下資金持續買入藥明生物,截至1月10日,其持股佔比由11%升至16.4%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.